When subcutaneous B78 melanoma tumors were rejected following treatment with a combination of radiation, anti-CTLA-4 and intra-tumoral injection of an immunocytokine (IL-2 fused to an antibody targeting disialoganglioside GD2), this led to rejection of intracranial tumors implanted 120 days post-rejection of extracranial tumors and was accompanied by enhanced infiltration of CD4+ and CD8+ T cells [48]. Here, CTLA4 is linked to melanoma.